Stockscreener 앱 받기
257.58
1.20%
-3.12
전일 마감가:
$260.70
열려 있는:
$260.14
하루 거래량:
933.43K
Relative Volume:
0.90
시가총액:
$37.60B
수익:
$5.26B
순이익/손실:
$1.44B
주가수익비율:
26.36
EPS:
9.7713
순현금흐름:
$1.76B
1주 성능:
+2.02%
1개월 성능:
+4.14%
6개월 성능:
+1.31%
1년 성능:
+8.62%
1일 변동 폭
$256.99
$261.04
1주일 범위
$250.32
$262.87
52주 변동 폭
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-09-02 | 업그레이드 | CLSA | Hold → Outperform |
| 2025-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 개시 | Morgan Stanley | Overweight |
| 2025-01-16 | 개시 | Goldman | Buy |
| 2025-01-10 | 개시 | Piper Sandler | Neutral |
| 2024-12-13 | 개시 | Stifel | Hold |
| 2024-09-24 | 개시 | Robert W. Baird | Outperform |
| 2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | 업그레이드 | Needham | Hold → Buy |
| 2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 개시 | UBS | Buy |
| 2023-04-14 | 개시 | Mizuho | Buy |
| 2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
| 2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
| 2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
| 2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
| 2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
| 2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
| 2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-06-22 | 개시 | Robert W. Baird | Neutral |
| 2021-06-21 | 재확인 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
| 2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Needham | Hold → Buy |
| 2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 개시 | CLSA | Underperform |
| 2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Perform |
| 2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
| 2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
Harel Insurance Investments & Financial Services Ltd. Lowers Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stephens Investment Management Group LLC Has $78.02 Million Stock Position in ResMed Inc. $RMD - MarketBeat
The Truth About ResMed Inc.: Sleep Tech Stock That Quietly Went Beast Mode - AD HOC NEWS
ResMed Inc. $RMD Shares Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Should ResMed's (RMD) Earnings Beat and Margin Gains Require Action From Investors? - Yahoo Finance
ResMed Inc. (NYSE:RMD) Embodies Quality Investing Principles - Chartmill
A Look At ResMed (RMD) Valuation After Earnings Beat And Strong Start To Fiscal 2026 - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Sleep Care Tailwinds? - Yahoo Finance
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today - sharewise.com
Resmed promotes new chief strategy officer from within - MassDevice
Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD) - Barchart.com
Shorts Report: Can ResMed Inc maintain sales growthWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Nordea Investment Management AB Acquires 26,629 Shares of ResMed Inc. $RMD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Buys 4,222 Shares of ResMed Inc. $RMD - MarketBeat
Reflecting On Patient Monitoring Stocks' Q3 Earnings: ResMed (NYSE:RMD) - Finviz
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - sharewise.com
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
ResMed Inc. Announces Change in Board Leadership - MSN
ResMed Chairman Emeritus Peter Farrell Sells 2,000 Shares Under Trading Plan - TipRanks
ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
ResMed updates CDI and share structure for December 2025 - MSN
Bogart Wealth LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Aug PostEarnings: What dividend growth rate does ResMed Inc offerJuly 2025 Gainers & Real-Time Buy Signal Notifications - baoquankhu1.vn
What you need to know ahead of ResMed's earnings release - MSN
Zacks Research Comments on ResMed's Q2 Earnings (NYSE:RMD) - MarketBeat
The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
How ResMed Inc. stock performs in easing cyclesIndex Update & Reliable Intraday Trade Alerts - ulpravda.ru
Resmed Insider Sold Shares Worth $497,660, According to a Recent SEC Filing - marketscreener.com
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com UK
Resmed director Farrell sells $497k in shares - Investing.com
SG Americas Securities LLC Acquires 47,758 Shares of ResMed Inc. $RMD - MarketBeat
Robeco Institutional Asset Management B.V. Sells 11,596 Shares of ResMed Inc. $RMD - MarketBeat
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsWeekly Trend Summary & Weekly Return Optimization Plans - ulpravda.ru
Will ResMed Inc. stock gain from lower inflationJuly 2025 Catalysts & Expert Curated Trade Setups - ulpravda.ru
Why ResMed Inc. (RME) stock is listed among top recommendations2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
EV Market: How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsPortfolio Return Report & Pattern Based Trade Signal System - ulpravda.ru
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Resmed Sets January 29 Date to Unveil Q2 FY2026 Results - TipRanks
ResMed CEO Michael Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - The Manila Times
Dow Theory LettersResmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - FinancialContent
Resmed Insider Sold Shares Worth $1,240,065, According to a Recent SEC Filing - marketscreener.com
Will ResMed Inc. stock deliver stable dividendsJuly 2025 Action & Verified Short-Term Plans - ulpravda.ru
How ResMed Inc. (RME) stock performs during market turbulenceQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Is ResMed Inc. (RME) stock protected from inflationEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
3.30%
자본화:
|
볼륨(24시간):